Platinum-resistant Ovarian Cancer Clinical Trial
Official title:
A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
This 2-part, Phase 1/2 study will test investigational cancer drugs known as CRS-207, epacadostat (IDO), and pembrolizumab (pembro). The purpose of this study is to find out how safe it is to give the investigational drugs to women with platinum-resistant ovarian, fallopian tube, or peritoneal cancer and if it helps patients with these types of cancer live longer or can help shrink or slow the growth of cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05494580 -
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05756907 -
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04787289 -
A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT04504916 -
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)
|
Phase 2 | |
| Recruiting |
NCT06090266 -
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05979298 -
Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer
|
Phase 2 | |
| Recruiting |
NCT04376073 -
Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06321484 -
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
|
Phase 1 | |
| Recruiting |
NCT05271318 -
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer.
|
Phase 1 | |
| Recruiting |
NCT06242470 -
A Study of MGC026 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05310344 -
Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer
|
Phase 2 | |
| Withdrawn |
NCT05736952 -
Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04374630 -
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian
|
Phase 2 | |
| Recruiting |
NCT05551507 -
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03949283 -
Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT06315491 -
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
|
Phase 2 | |
| Recruiting |
NCT05870748 -
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05198804 -
A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT04718376 -
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer
|
Phase 1 | |
| Recruiting |
NCT05081609 -
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
|
Phase 1/Phase 2 |